Back to Search
Start Over
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
- Source :
- HemaSphere, Vol 5, Iss 2, p e524 (2021), Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, HemaSphere, 5(2):e524. Wolters Kluwer Health, HemaSphere, HemaSphere. Wolters Kluwer Health
- Publication Year :
- 2021
- Publisher :
- Wolters Kluwer, 2021.
-
Abstract
- Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the costs and budget impact associated with CAR T-cell therapies for current and future indications in hematological cancers from 2019 to 2029. We focused on the former France, Germany, Spain, Italy and the United Kingdom (EU-5) and the Netherlands. We conducted a review of list prices, health technology assessment reports, budget impact analysis dossiers, and published cost-effectiveness analyses. We forecasted the 10-year health expenditures on CAR T-cells for several hematological cancers in selected European Union countries. Nine cost-effectiveness studies were identified and list prices for CAR T-cell therapies ranged between 307 200 EUR and 350 000 EUR. Estimated additional costs for pre- and post-treatment were 50 359 EUR per patient, whereas the incremental costs of CAR T-cell therapy (when compared with care as usual) ranged between 276 086 EUR and 328 727 EUR. We estimated market entry of CAR T-cell therapies for chronic mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia in 2021, 2022, 2022, 2022, and 2025, respectively. Cumulative expenditure estimates for existing and future indications from 2019 to 2029 were on average 28.5 billion EUR, 32.8 billion EUR, and 28.9 billion EUR when considering CAR T-cell therapy costs only, CAR T-cell therapy costs including pre- and post-treatment, and incremental CAR T-cell therapy costs, respectively. CAR T-cell therapies seem to be promising treatment options for hematological cancers but the financial burden on healthcare systems in the former EU-5 and the Netherlands will contribute to a substantial rise in healthcare expenditure in the field of hematology.
- Subjects :
- medicine.medical_specialty
Hematology
business.industry
Chronic lymphocytic leukemia
MEDLINE
Treatment options
Health technology
medicine.disease
Chimeric antigen receptor
Article
SDG 3 - Good Health and Well-being
Internal medicine
Health care
Medicine
media_common.cataloged_instance
Diseases of the blood and blood-forming organs
European union
RC633-647.5
business
Intensive care medicine
health care economics and organizations
media_common
Subjects
Details
- Language :
- English
- ISSN :
- 25729241
- Volume :
- 5
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- HemaSphere
- Accession number :
- edsair.doi.dedup.....e2b66b6306555d78d7d1f444d8ceb14f